ストックスクリーナーアプリを入手
0.3625
3.42%
0.012
アフターアワーズ：
.35
-0.0125
-3.45%
前日終値:
$0.3505
開ける：
$0.36
24時間の取引高:
192.87K
Relative Volume:
1.11
時価総額：
$16.47M
収益：
-
当期純損益:
$-74.56M
株価収益率:
-0.1979
EPS:
-1.8316
ネットキャッシュフロー:
$-60.27M
1週間 パフォーマンス:
+11.16%
1か月 パフォーマンス:
+10.08%
6か月 パフォーマンス:
-60.60%
1年 パフォーマンス:
-74.11%
1日の値動き範囲:
$0.348
$0.37
1週間の範囲:
$0.30
$0.3796
52週間の値動き範囲:
$0.2201
$1.54
Rallybio Corp Stock (RLYB) Company Profile
RLYB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.3625 | 16.47M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-02-07 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-17 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-10 | 開始されました | Wedbush | Outperform |
| 2022-12-09 | 開始されました | JP Morgan | Overweight |
| 2022-02-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-08-23 | 開始されました | Cowen | Outperform |
| 2021-08-23 | 開始されました | Evercore ISI | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
すべてを表示
Rallybio Corp (RLYB) 最新ニュース
Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study - TradingView
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 By Investing.com - Investing.com South Africa
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - BioSpace
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 - Investing.com India
Rallybio Initiates Dosing In RLYB116 Phase 1 Confirmatory Study - MarketScreener
Rallybio's $5B Market Opportunity: New Phase 1 Trial Targets Two Untreated Rare Blood Disorders - Stock Titan
RLYBRallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - mx.advfn.com
Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio - Trumbull Times
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook By Investing.com - Investing.com Canada
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook - Investing.com
Rallybio shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Rallybio shareholders elect directors, ratify auditor - Investing.com
Rallybio Elects New Directors at Shareholder Meeting - TipRanks
Rallybio Reports Q1 2025 Financial Results and Strategic Updates - MSN
New Haven biotech firm to cut 40% of workforce in latest round of layoffs, pivots on drug program - Stamford Advocate
Rallybio Downsizes by 40% After Dropping Lead Asset - BioSpace
Layoffs hit biotech: Vor Bio slashes 95% of staff, more cuts from insitro, Korro, Rallybio - FirstWord Pharma
4 more biotechs cut staff amid market tumult - BioPharma Dive
Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Another CT biotech company making significant workforce cuts - Hartford Business Journal
RallyBio cuts deeper, laying off 40% of workforce after halting work on lead drug - Fierce Biotech
Rallybio Corp SEC 10-Q Report - TradingView
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates - Bluefield Daily Telegraph
Rallybio (RLYB) to Release Quarterly Earnings on Thursday - Defense World
Renaissance Technologies LLC Has $424,000 Stock Position in Rallybio Co. (NASDAQ:RLYB) - Defense World
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference - BioSpace
Rallybio Makes Nasdaq Debut - RTTNews
Citizens JMP maintains Rallybio stock at Market Perform By Investing.com - Investing.com Nigeria
Citizens JMP maintains Rallybio stock at Market Perform - Investing.com
Rallybio (NASDAQ:RLYB) Cut to Hold at Evercore ISI - Defense World
Rallybio drops drug for rare maternal disorder following Phase II fail - MSN
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Evercore ISI Downgrades Rallybio to In Line From Outperform - marketscreener.com
Analysts Set Rallybio Co. (NASDAQ:RLYB) Price Target at $9.75 - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns - Investing.com Australia
HC Wainwright Estimates Rallybio’s Q2 Earnings (NASDAQ:RLYB) - Defense World
Rallybio’s (RLYB) Neutral Rating Reiterated at HC Wainwright - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns By Investing.com - Investing.com India
Rallybio (NASDAQ:RLYB) Cut to Hold at Citizens Jmp - Defense World
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
Rallybio Corp (RLYB) 財務データ
収益
当期純利益
現金流量
EPS
1.02%
1.78%
大文字化:
|
ボリューム (24 時間):